TNYA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient trader. While near-term momentum has improved (positive/expanding MACD) and options positioning is aggressively call-skewed, the broader trend remains bearish (SMA_200 > SMA_20 > SMA_5), the stock is sitting just below a key resistance zone (~0.792–0.83), and there are no fresh news catalysts this week to force an immediate breakout. This setup looks more like a wait-for-confirmation trade than an “buy now” trade.
Price is ~0.775 post-market after a -1.94% regular-session drop, stabilizing slightly after hours. Momentum is improving: MACD histogram is positive (0.0204) and expanding, suggesting a short-term rebound attempt. RSI(6) ~60 is neutral-to-slightly-bullish (not overbought). However, the moving-average stack is still bearish (SMA_200 > SMA_20 > SMA_5), implying the dominant trend remains down. Key levels: Pivot ~0.73 (important near-term support); resistance at R1 ~0.792 (immediate ceiling) and R2 ~0.83. With price just under R1, the risk/reward for an impatient entry is unattractive unless it clears ~0.792 convincingly; otherwise, a slip back toward ~0.73 is plausible.
Prior clinical catalyst remains constructive: FDA lifted the clinical hold on the MyPEAK-1 trial (TN-
and interim RIDGE-1 Ph1B TN-401 data provided proof-of-concept, with further updates expected in 1H 2026 (per analyst notes).
Street remains broadly positive on the science (Buy/Overweight ratings maintained despite target cuts).
Pattern-based projection provided suggests mild upside bias over 1 week to 1 month (+0.64% week; +2.61% month).
Trend structure is still bearish (long-term downtrend indicated by moving averages), and price is near resistance (~0.792–0.83), increasing odds of a stall/pullback rather than an immediate breakout.
Dilution overhang: multiple analysts explicitly lowered targets due to equity offering-related dilution.
No new news this week—limited near-term catalyst pressure to re-rate the stock immediately.
Biotech cash-burn profile remains evident in financials (continued losses with essentially no revenue).
Latest reported quarter: 2025/Q3. Revenue was 0 (no meaningful commercial revenue). Net loss widened to -$20.275M (down -20.91% YoY), and EPS fell to -$0.12 (down -60% YoY). Overall: worsening bottom-line trend and continued development-stage financial profile, which typically increases sensitivity to financing/dilution and clinical headlines.
Recent analyst trend: ratings stayed positive (Buy/Overweight maintained), but price targets were cut meaningfully. Morgan Stanley (2026-01-08) kept Overweight but cut PT to $2 from $5. Canaccord (2025-12-18) kept Buy but cut PT to $4 from $6. Chardan (2025-12-12) kept Buy, cut PT to $8 from $9 (explicitly citing dilution). H.C. Wainwright (2025-12-12) kept Buy, cut PT to $3 from $5 (dilution). Wall Street pros: constructive view on pipeline progress and competitive positioning in PKP2-ACM with upcoming updates in 1H 2026. Cons: dilution/financing risk and lack of near-term revenue, plus competitive landscape (LXEO, RCKT) with updates expected into 2026.
